Bupropion Sustained Release Treatment Reduces Fatigue in Cancer Patients

Cullum, Jodi L; Wojciechowski, Agnieszka E; Pelletier, G.; Simpson, Jennifer S.

doi:10.1177/070674370404900209

Cited by 73 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most drugs were not compared with placebo or did not show significant benefit compared with placebo (Fig. 3) [7,8,[103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118]. One drug, methylphenidate, showed promising results [111][112][113]119], but in the latest and largest trials, no improvement of fatigue by this treatment was found compared with placebo [114,120,121].…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Neefjes

Vorst

Blauwhoff‐Buskermolen

et al. 2013

The Oncologist

View full text Add to dashboard Cite

Cancer-related fatigue (CRF) is a serious symptom of patients with cancer and deteriorates their daily quality of life. Whereas fatigue is a common problem in the general population, with a prevalence of about 30%, up to 99% of patients with cancer have fatigue of more intense severity. CRF is directly related to the biology of cancer, but it can also be caused by anticancer treatment. We reviewed current evidence about the potential pathophysiological mechanisms causing CRF. Clinical methods to determine the presence and severity of CRF and potential treatment options to reduce CRF will be discussed. After reading this review, the reader will have knowledge of the current understanding of CRF and will be able to give evidence-based advice to patients with CRF. The Oncologist 2013;18:1135-1143Implications for Practice: Cancer-related fatigue (CRF) is a common problem in patients with cancer and has a major impact on quality of life. The causes of CRF are multifactorial and not fully understood. To get a better insight into the underlying mechanisms and the potential treatment possibilities of CRF, we provide an overview of currently available literature on this subject. Because current treatment options other than antitumor therapy for some of the patients are scarce and only directed at symptoms, further investigation of CRF is warranted to develop rational treatment options.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 99%

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Neefjes

Vorst

Blauwhoff‐Buskermolen

et al. 2013

The Oncologist

View full text Add to dashboard Cite

show abstract

“…64 Bupropion has reduced fatigue in cancer patients and may lower tumor necrosis factor alpha but is a second-line agent in advanced disease because of seizure risk. 65,66 Tricyclics are effective for depression in cancer patients but are also second-line agents because of their frequent side effects (Table 2).…”

Section: Treatmentmentioning

confidence: 99%

Psychiatric disorders in advanced cancer

Miovic

Block

2007

Cancer

320

228

View full text Add to dashboard Cite

Label‐free microcolony identification via elastic light scattering was investigated for three different genera: Salmonella enterica serovar Montevideo, Listeria monocytogenes F4244, and Escherichia coli DH5α. Microcolonies were defined as bacterial colonies in their late‐lag phase to early‐exponential phase with the diameter range of 100–200 µm. To link biophysical characteristics with corresponding scattering patterns, a phase contrast microscope and a confocal displacement meter were used to measure the colony diameter and its 3D height profile. The results indicated that the growth characteristics of microcolonies were encoded in their morphologies which correlated to the characteristic diffraction patterns. Proposed methodology was able to classify three genera based on comprehensive phenotypic map which incorporated growth speed, ring count, and colony diameter. While the proposed method illustrated the possibility of discriminating microcolonies in their early growth stage, more thorough biophysical understanding is needed to expand the technology to other species. Biotechnol. Bioeng. 2011; 108:637–644. © 2010 Wiley Periodicals, Inc.

show abstract

“…Bupropion (Wellbutrin-SR ® ; GlaxoSmithKline, Philadelphia) is an atypical antidepressant, unrelated to tricyclic antidepressants or selective serotonin reuptake inhibitors, that has been used to treat chronic fatigue syndrome and fatigue associated with multiple sclerosis [62][63][64]. We identified two studies (6% of total) of bupropion sustained-release (SR) in the treatment of CRF [42,43]. In these open-label case series, bupropion SR (100-300 mg/day) was associated with improvements in fatigue scores within 2-4 weeks of the start of treatment.…”

Section: Antidepressantsmentioning

confidence: 99%

Pharmacologic Treatment of Cancer-Related Fatigue

et al. 2007

View full text Add to dashboard Cite

Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. This paper systematically reviews pharmacologic agents in the treatment of cancer-related fatigue (CRF). We conducted a literature review of clinical trials that assessed pharmacologic agents for the treatment of CRF. These agents include hematopoietics (for anemia), corticosteroids, and psychostimulants. Other therapeutic agents that are less well studied for CRF but are currently the focus of clinical trials include l-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine. The Oncologist 2007;12(suppl 1):43-51

show abstract

Bupropion Sustained Release Treatment Reduces Fatigue in Cancer Patients

Cited by 73 publications

References 36 publications

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Psychiatric disorders in advanced cancer

Pharmacologic Treatment of Cancer-Related Fatigue

Contact Info

Product

Resources

About